Since the first reported case of the novel coronavirus (SARS-CoV-2) in humans at the endof 2019 in Wuhan, the virus had infected approximately 100 million individuals. One yearlater, coronavirus disease (COVID-19) was estimated to have affected nearly 30% of theglobal population, with a case fatality rate of approximately 2%. In the early stages ofthe pandemic, numerous questions emerged regarding this novel viral agent, including itspathogenic mechanisms, associated vulnerabilities, risk factors, and potential treatmentstrategies. A wide spectrum of clinical conditions-including chronic diseases, infectiousagents, autoimmune disorders, and even genetic or post-therapeutic alterations-cantrigger inflammatory syndromes in the human body. A central component of these processesis the dysregulation of cytokine signaling, which may provoke excessive immune cellactivation, leading to a self-perpetuating inflammatory loop with potentiallylife-threatening consequences. Notably, both SARS-CoV-2 infection and elevated C-reactiveprotein (CRP) levels have been consistently observed during active disease states.Furthermore, vitamin E is well known as an antioxidant that prevents the peroxidation oflipid molecules, as ferroptosis. A well-established phenomenon is that lipid peroxidationlevels are higher in COVID-19 patients, while antioxidant capacity is diminished.Therefore, the aim of this study is to evaluate CRP levels in COVID-19 patientsadministered high doses of vitamin E (alpha-tocopherol)-a lipid-solubleantioxidant-compared to those receiving a placebo.